Aethlon Medical Receives Ethics Board Approval To Add Second Site To Its Ongoing Clinical Trial Of Its Hemopurifier To Treat Severe COVID-19 In India
Portfolio Pulse from Benzinga Newsdesk
Aethlon Medical (NASDAQ:AEMD) has received Ethics Review Board approval to add a second site, Maulana Azad Medical College, to its ongoing clinical trial of Hemopurifier for treating severe COVID-19 in India. The trial aims to enroll up to 15 patients across three centers.
May 22, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Aethlon Medical's ongoing clinical trial of Hemopurifier for severe COVID-19 treatment in India has received approval to add a second site.
While the addition of a second site to Aethlon Medical's ongoing clinical trial of Hemopurifier for severe COVID-19 treatment in India is positive news for the company, it is unlikely to have a significant short-term impact on INDA, an ETF tracking the Indian stock market, as the trial is still in its early stages and the overall impact on the Indian market is limited.
CONFIDENCE 80
IMPORTANCE 40
RELEVANCE 50
POSITIVE IMPACT
Aethlon Medical's ongoing clinical trial of Hemopurifier for severe COVID-19 treatment in India has received approval to add a second site.
The addition of a second site to Aethlon Medical's ongoing clinical trial of Hemopurifier for severe COVID-19 treatment in India increases the potential for patient enrollment and accelerates the trial process. This could lead to faster results and potentially positive news for the company, which may positively impact AEMD's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100